Henrik Schmidt

14.0k total citations · 2 hit papers
96 papers, 3.6k citations indexed

About

Henrik Schmidt is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Henrik Schmidt has authored 96 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 43 papers in Molecular Biology and 40 papers in Immunology. Recurrent topics in Henrik Schmidt's work include Cancer Immunotherapy and Biomarkers (37 papers), Immunotherapy and Immune Responses (32 papers) and CAR-T cell therapy research (29 papers). Henrik Schmidt is often cited by papers focused on Cancer Immunotherapy and Biomarkers (37 papers), Immunotherapy and Immune Responses (32 papers) and CAR-T cell therapy research (29 papers). Henrik Schmidt collaborates with scholars based in Denmark, United States and France. Henrik Schmidt's co-authors include Omid Hamid, Torben Steiniche, Scott D. Chasalow, Lars Bastholt, David M. Berman, Trine Øllegaard Jensen, Ib Jarle Christensen, Pia Sjoegren, Maria Jure–Kunkel and Holger Jon Møller and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer.

In The Last Decade

Henrik Schmidt

94 papers receiving 3.6k citations

Hit Papers

An immune-active tumor microenvironment favors clinical r... 2011 2026 2016 2021 2011 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An immune-active tumor microenvironment favors clinical response to ipilimumab
    2011 593 citations Omid Hamid, Henrik Schmidt et al. profile →
  2. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
    2016 281 citations Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research profile →

Peers

Henrik Schmidt
Jon M. Wigginton United States
Alexander C. Huang United States
Tahseen H. Nasti United States
Romain Remark France
Matthew D. Vesely United States
Antonella Sistigu Italy
Catherine Koebel United States
Weiyi Peng United States
Saskia J. Santegoets Netherlands
Protul Shrikant United States
Jon M. Wigginton United States
Henrik Schmidt
Citations per year, relative to Henrik Schmidt Henrik Schmidt (= 1×) peers Jon M. Wigginton

Countries citing papers authored by Henrik Schmidt

Since Specialization
Citations

This map shows the geographic impact of Henrik Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Schmidt more than expected).

Fields of papers citing papers by Henrik Schmidt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Schmidt. The network helps show where Henrik Schmidt may publish in the future.

Co-authorship network of co-authors of Henrik Schmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Schmidt. A scholar is included among the top collaborators of Henrik Schmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Schmidt. Henrik Schmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Nørgaard, Mette, et al.. (2025). Risk of and Mortality After Acute Kidney Injury Following Cancer Treatment: A Cohort Study. Cancer Medicine. 14(3). e70646–e70646. 1 indexed citations
3.
Greisen, Stinne Ravn, Malene Hvid, Jakob Hauge Mikkelsen, et al.. (2024). Gal-3 blocks the binding between PD-1 and pembrolizumab. Journal for ImmunoTherapy of Cancer. 12(10). e009952–e009952.
4.
Brink, Carsten, Thomas Heiberg Brix, Eva Ellebæk, et al.. (2024). Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study. Supportive Care in Cancer. 32(5). 281–281. 1 indexed citations
5.
Hansen, Christian Rønn, Eva Ellebæk, Henrik Schmidt, et al.. (2024). Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study. European Journal of Cancer. 205. 114099–114099. 3 indexed citations
6.
Mapendano, Christophe K., Christina H. Ruhlmann, Inge Marie Svane, et al.. (2024). Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort. Cancers. 16(14). 2559–2559. 1 indexed citations
7.
Kjellberg, Jakob, et al.. (2023). Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma. European Journal of Cancer. 192. 113288–113288. 2 indexed citations
8.
Haslund, Charlotte Aaquist, Henrik Schmidt, Lars Bastholt, et al.. (2023). Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies. European Journal of Cancer. 195. 113392–113392. 6 indexed citations
9.
Schmidt, Henrik, et al.. (2023). Psychological and behavioral symptoms in patients with melanoma: A systematic review and meta‐analysis. Psycho-Oncology. 32(8). 1208–1222. 13 indexed citations
10.
Ellebæk, Eva, Shawez Khan, Lars Bastholt, et al.. (2023). PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. European Journal of Cancer. 198. 113476–113476. 18 indexed citations
11.
12.
13.
Jensen, Christina, Dovilė Sinkevičiūtė, Daniel H. Madsen, et al.. (2020). Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade. Cancers. 12(10). 2786–2786. 34 indexed citations
14.
Ferrucci, Pier Francesco, Anna Maria Di Giacomo, Michele Del Vecchio, et al.. (2020). KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer. 8(2). e001806–e001806. 111 indexed citations
15.
Nielsen, Berit Kjærside, et al.. (2020). The impact of patient involvement in research: a case study of the planning, conduct and dissemination of a clinical, controlled trial. Research Involvement and Engagement. 6(1). 43–43. 58 indexed citations
16.
Eggermont, Alexander M.M., Vanna Chiarion‐Sileni, Jean-Jacques Grob, et al.. (2019). Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer. 119. 1–10. 123 indexed citations
17.
Segal, Neil H., Theodore F. Logan, F. Stephen Hodi, et al.. (2016). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. 23(8). 1929–1936. 281 indexed citations breakdown →
18.
Frøslev, Trine, et al.. (2013). The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987–2009: a registry-based cohort study. British Journal of Cancer. 109(1). 265–271. 33 indexed citations
19.
Weischer, Maren, Ida M. Heerfordt, Stig E. Bojesen, et al.. (2011). CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis. Journal of Investigative Dermatology. 132(2). 299–303. 24 indexed citations
20.
Schmidt, Henrik, Julia S. Johansen, Julie Gehl, et al.. (2006). Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 106(5). 1130–1139. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jon M. Wigginton Breakdown of academic impact, for papers by Alexander C. Huang Breakdown of academic impact, for papers by Tahseen H. Nasti Breakdown of academic impact, for papers by Romain Remark Breakdown of academic impact, for papers by Matthew D. Vesely Breakdown of academic impact, for papers by Antonella Sistigu Breakdown of academic impact, for papers by Catherine Koebel Breakdown of academic impact, for papers by Weiyi Peng Breakdown of academic impact, for papers by Saskia J. Santegoets Breakdown of academic impact, for papers by Protul Shrikant
Rankless by CCL
2026